Dundee – Confidence in Concept 2019
Lead Research Organisation:
University of Dundee
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Publications
Armstrong LA
(2021)
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies.
in PloS one
Long MB
(2024)
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection.
in The European respiratory journal
Pearson LA
(2021)
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
in SLAS discovery : advancing life sciences R & D
| Description | COVID-19 Lead Optimisation of New Broad-Spectrum Drug Candidate |
| Amount | £4,871,348 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 03/2021 |
| End | 05/2023 |
| Description | Harnessing the splicing code for targeted control of gene expression (UNLEASH) |
| Amount | £2,117,288 (GBP) |
| Funding ID | EP/Y010655/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 05/2029 |
| Description | Callaboration with Bukwang - second program |
| Organisation | Bukwang Pharmaceutical |
| Country | Korea, Republic of |
| Sector | Private |
| PI Contribution | Provided the primary biology that allowed hit discovery for a new drug discovery project |
| Collaborator Contribution | Funding and route to clinical trials if successful |
| Impact | none so far |
| Start Year | 2021 |
| Description | Partnership with Exeed |
| Organisation | Epidarex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discovery of small molecule inhibitors of a methyltransferase - patent on structural platform |
| Collaborator Contribution | Funding and scientific input into aligning the pharmacological profile with a commercial disease indication |
| Impact | none as yet |
| Start Year | 2021 |
| Description | ValiRx due diligence |
| Organisation | ValiRx |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Collaboration with QMUL to find molecules that push cells into senescence. Compounds, medicinal chemistry to improve them from DDU. Screening assay with QMUL. Disease alignment assays from ValiRX. Intent is to form a Newco. This information and financial terms are confidential. |
| Collaborator Contribution | Screening assay with QMUL. Disease alignment assays from ValiRX. Intent is to form a Newco. This information and financial terms are confidential. |
| Impact | New funding from QMUL and other funding from ValiRX |
| Start Year | 2024 |
| Title | Patent applied for describing RNMT inhibitors |
| Description | small molecule inhibitors of RNMT |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | 2024 |
| Licensed | No |